AbCellera

Name

AbCellera

Legal name

AbCellera Biologics Inc.

Website

https://abcellera.com

Company type

Public

Founded year

2012

Operating status

Operating

Headcount range

501–1,000 employees

Ownership category

akta.pro rank

Product category

Biopharmaceutical Antibody Therapeutics

NAICS

Biological Product (except Diagnostic) Manufacturing (325414), Research and Development in Biotechnology (except Nanobiotechnology) (541714), Pharmaceutical and Medicine Manufacturing (3254)

SIC

Biological Products, (No Disgnostic Substances) (2836), Pharmaceutical Preparations (2834)

akta.pro primary industry

Antibody Discovery & Engineering Platforms (display tech, bispecifics, Fc engineering) (HLAAAIAB)

akta.pro secondary industries

AI/ML-Enabled Biologic Discovery Platforms (computational design, in silico screening) (HLAAAIAE), Monoclonal Antibody Therapeutics (mAbs) (HLAAAAAA), Immunology & Autoimmune Specialty Pharmaceuticals (HLAIACAB)

Keywords

• Antibody drug discovery
• Therapeutic antibody development
• Bispecific antibody engineering
• Microfluidic single-cell screening
• Clinical antibody manufacturing

Headquarters

HQ city

Vancouver

HQ country

Canada

HQ region

North America

Offices4 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Technology or R&D, Personnel, Infrastructure, Operations, Marketing or Sales

Revenue model

1. Partnership and Collaboration Revenue: AbCellera generates revenue through research collaborations with pharmaceutical and biotech partners, receiving upfront payments, research funding, milestone payments upon achievement of development milestones, and tiered royalties on net sales of approved products.
2. Internal Pipeline Development: Company is transitioning from pure partnership model to developing proprietary drug candidates through clinical trials, with potential for future product revenue

Go-to-market motion1 record

Distribution channels1 record

Marketing channels3 records

Core offering

AbCellera discovers and develops therapeutic antibody medicines using an integrated platform that combines proprietary microfluidic single-cell screening, AI-driven analysis, transgenic mouse technologies, and GMP clinical manufacturing. The company partners with pharmaceutical and biotechnology companies for antibody discovery programs (generating upfront, milestone, and royalty payments) while also advancing an internal proprietary pipeline of antibody candidates in women's health, immunology, autoimmunity, and oncology.

Product overview

AbCellera is a clinical-stage biotechnology company that operates an integrated antibody discovery and development platform. The core offering is a technology platform that combines microfluidics, single-cell screening, AI, and transgenic mouse technologies to discover therapeutic antibodies. The company is advancing an internal pipeline of antibody programs including ABCL635 (NK3R for menopausal vasomotor symptoms in Phase 2), ABCL575 (OX40L for atopic dermatitis in Phase 1), ABCL688 (autoimmunity, IND-enabling), and ABCL386 (oncology). The platform capabilities include T-cell engager technology for bispecific antibody development and GPCR/ion channel technologies for complex membrane protein targets. AbCellera also operates a 130,000 sq ft GMP clinical manufacturing facility in Vancouver. The company partners with pharmaceutical companies including Lilly, AbbVie, Jazz, and others for discovery programs while building its proprietary pipeline.

Differentiator

Problem solved

Functional benefit

Products and services

• Antibody Discovery Platform Integrated antibody discovery service combining proprietary microfluidic single-cell screening, AI-driven analysis, and transgenic mouse technologies to discover and generate therapeutic antibody candidates from natural immune responses, contracted by pharmaceutical and biotech partners.
• ABCL635 First-in-class antibody medicine targeting NK3R for the non-hormonal treatment of moderate-to-severe vasomotor symptoms (hot flashes) associated with menopause; first AbCellera-led program generated using GPCR and ion channel technologies, currently in Phase 1/2 clinical trials.
• ABCL575 Investigative monoclonal antibody targeting OX40L with a modified Fc domain for treatment of moderate-to-severe atopic dermatitis, with potential applications to other inflammatory and autoimmune conditions; currently in Phase 1 clinical trial.
• ABCL688 Potential antibody medicine targeting a multipass complex membrane protein for treatment of an undisclosed indication in autoimmunity; second AbCellera-led program generated using GPCR and ion channel technologies, currently in IND-enabling studies.
• ABCL386 Potential antibody medicine for treatment of an undisclosed indication in oncology, part of AbCellera's internal proprietary pipeline.
• T-Cell Engager Platform Platform for designing and engineering T-cell engaging bispecific antibodies to address challenging tumor types by incorporating novel CD3, co-stimulatory (CD28, 4-1BB), and multispecific modalities for oncology and immunology applications; partnered with Jazz Pharmaceuticals, AbbVie, and others.

Quantifiable outcome

• 100+ antibody drug programs completed with 16 candidates reaching clinical stage
• +3 more outcomes

Named customers8 records

Segments4 records

Ideal customer profiles1 record

Technology focussed Yes

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

AI capability3 records

Feature4 records

Partnerships

Ten partnerships are on record, tiered major and core.

• Jazz PharmaceuticalsmajorStrategic or Co-development Partner · 17 June 2026Preclinical research collaboration, option and license agreement to discover and develop next-generation T-cell engaging multispecific antibodies targeting gastrointestinal cancers and solid tumors. AbCellera receives $56M upfront for first two programs ($28M additional for third), with potential milestone payments up to $792M per program plus tiered royalties on net sales. Jazz receives exclusive worldwide development and commercialization rights.
• Eli LillycoreStrategic or Co-development PartnerExpanded partnership from 2020 collaboration (which produced COVID-19 antibodies bamlanivimab and bebtelovimab) to discover therapeutic antibodies in immunology, cardiovascular disease, and neuroscience. Lilly gains development and commercialization rights while AbCellera receives upfront, milestone, and royalty payments.
• AbbViecoreStrategic or Co-development PartnerExpanded collaboration to develop novel T-cell engagers for oncology, building on existing partnership relationship.
• RegeneroncoreStrategic or Co-development PartnerPartner for antibody drug discovery programs across various therapeutic areas.
• NovartiscoreStrategic or Co-development PartnerPartner for antibody drug discovery programs across various therapeutic areas.
• IncytecoreStrategic or Co-development PartnerPartner for antibody drug discovery programs across various therapeutic areas.
• BiogencoreStrategic or Co-development PartnerPartner for antibody drug discovery programs across various therapeutic areas.
• GileadcoreStrategic or Co-development PartnerPartner for antibody drug discovery programs across various therapeutic areas.
• Prelude TherapeuticscoreStrategic or Co-development PartnerPartner for antibody drug discovery programs across various therapeutic areas.
• EmpiricocoreStrategic or Co-development PartnerPartner leveraging AbCellera's technology for target discovery and validation with best-in-class antibodies to advance genetically validated targets into potential antibody-based therapies.

Scale indicators8 records

Recent moves7 records

Expansion highlights5 records

Direct peers

• Adimab: Adimab operates a leading yeast-based antibody discovery platform serving pharma and biotech partners through licensing and collaboration agreements. Direct comparable to AbCellera in the antibody discovery platform-as-a-service model, though using different core technology (yeast display vs. microfluidics).
• Absci: Absci is an AI-powered generative antibody discovery company combining high-throughput wet lab capabilities with deep learning models. Closely comparable to AbCellera in combining AI/ML-driven antibody design with proprietary wet-lab infrastructure for biologics discovery.
• Genmab: Genmab is a clinical and commercial-stage antibody therapeutics company with proprietary technology platforms (DuoBody, HexaBody, etc.) and a deep pipeline of partnered and proprietary antibody medicines. Comparable to AbCellera as a platform-driven antibody company generating revenue through partnerships and product royalties.
• argenx: argenx is a commercial-stage immunology-focused antibody therapeutics company with its own proprietary antibody discovery platform (SIMPLE Antibody) and a portfolio of approved products including VYVGART. Comparable to AbCellera's transition toward proprietary clinical pipeline, with overlapping focus on immunology indications.
• MacroGenics: MacroGenics is a clinical-stage biopharmaceutical company focused on antibody-based therapeutics for cancer and autoimmune disease, with proprietary DART and TRIDENT platforms for bispecific antibodies. Directly comparable to AbCellera's T-cell engager platform and clinical-stage antibody pipeline.

Broad incumbents

• Regeneron Pharmaceuticals: Regeneron is a large established biopharmaceutical company with its own proprietary VelociSuite antibody discovery technologies and a deep pipeline of approved antibody medicines. Functions as both an AbCellera partner and a competitor demonstrating how incumbents build internal antibody capabilities.
• Eli Lilly: Eli Lilly is one of AbCellera's largest pharma partners (COVID-19 antibodies, immunology, cardiovascular, neuroscience collaborations). As a global pharma major with growing in-house biologics capabilities, Lilly represents both the most significant partnership counterparty and a potential long-term competitive threat in antibody discovery.

Emerging players

• Generate Biomedicines: Generate Biomedicines is an emerging AI-driven generative biology company focused on designing novel protein therapeutics including antibodies using foundation models. Represents a next-generation competitor to AbCellera's AI-enabled antibody discovery approach with backing from Flagship Pioneering.
• Schrödinger: Schrödinger operates a physics-based computational platform for drug discovery and materials science, including antibody and biologics design capabilities. Comparable to AbCellera's AI/ML-driven approach to therapeutic design, though broader in scope (small molecules plus biologics).
• Recursion Pharmaceuticals: Recursion is an AI-driven drug discovery company combining high-throughput biology, automation, and machine learning to discover novel therapeutics. Comparable to AbCellera's data-driven approach to biologics discovery, though focused on small molecules and broader indication areas.

Market position

Strengths5 records

Weaknesses4 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

• LinkedInlinkedin.com/company/abcellera
• Xx.com/abcellerabio

Revenue estimate

Valuation estimate

Number of profiles

Profiles10 records

Funding overview

Funding rounds11 records

Investors12 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A4 records

Investments2 records

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about AbCellera